Etrolizumab in UC: Etrolizumab/placebo for patients who are refractory/intolerant to TNF inhibitors

Print

Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989
smikolainis@mtsinai.on.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectation: Cohort 1: completed, Cohort 2: drug/placebo 4:1 ratio for 14 weeks, following week 14 is the Maintenance phase for those who are responders, they will receive either drug/placebo, open label extension possible for non-responders

Eligibility

  • Mayo score 6-12 (bleeding subscore >1)
  • Anti-TNF washout – 8weeks prior to Day 1
  • Intolerant or refractory to either: Infliximab, Adalimumab or Golimumab within past 5 years or recurrence or symptoms or intolerance
  • Subcutaneous injection


Exclusions: strictures, prior tx with anti-integrin agents (vedolizumab)

WE INVITE YOU TO PARTNER WITH US TODAY
Donate to the Zane Cohen Centre
Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex. Copyright © 1997 - 2017.
All Rights Reserved. A patient care, teaching and research centre affiliated with University of Toronto.
Powered by Joomla 1.7 Templates